Celgene Co. (CELG) Stake Lifted by Mackay Shields LLC

Mackay Shields LLC raised its position in Celgene Co. (NASDAQ:CELG) by 112.4% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 427,910 shares of the biopharmaceutical company’s stock after purchasing an additional 226,493 shares during the period. Mackay Shields LLC owned 0.06% of Celgene worth $27,425,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Oregon Public Employees Retirement Fund lifted its position in shares of Celgene by 9,691.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 16,495,997 shares of the biopharmaceutical company’s stock valued at $257,000 after acquiring an additional 16,327,522 shares during the period. Parnassus Investments CA lifted its position in shares of Celgene by 1,766.7% during the 4th quarter. Parnassus Investments CA now owns 2,800,000 shares of the biopharmaceutical company’s stock valued at $179,452,000 after acquiring an additional 2,650,000 shares during the period. FMR LLC lifted its position in shares of Celgene by 26.0% during the 3rd quarter. FMR LLC now owns 10,279,258 shares of the biopharmaceutical company’s stock valued at $919,890,000 after acquiring an additional 2,119,257 shares during the period. Edgewood Management LLC lifted its position in shares of Celgene by 13.2% during the 3rd quarter. Edgewood Management LLC now owns 15,757,525 shares of the biopharmaceutical company’s stock valued at $1,410,141,000 after acquiring an additional 1,832,981 shares during the period. Finally, BlackRock Inc. lifted its position in shares of Celgene by 2.8% during the 4th quarter. BlackRock Inc. now owns 53,650,909 shares of the biopharmaceutical company’s stock valued at $3,438,486,000 after acquiring an additional 1,459,100 shares during the period. Hedge funds and other institutional investors own 74.19% of the company’s stock.

In other news, Director James J. Loughlin sold 23,466 shares of the company’s stock in a transaction on Thursday, February 7th. The shares were sold at an average price of $87.29, for a total value of $2,048,347.14. Following the completion of the sale, the director now owns 62,102 shares in the company, valued at approximately $5,420,883.58. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ernest Mario bought 2,000 shares of Celgene stock in a transaction dated Tuesday, February 12th. The stock was purchased at an average price of $89.99 per share, with a total value of $179,980.00. The disclosure for this purchase can be found here. Corporate insiders own 0.39% of the company’s stock.

CELG opened at $88.46 on Friday. The company has a debt-to-equity ratio of 3.21, a quick ratio of 2.12 and a current ratio of 2.23. Celgene Co. has a 1-year low of $58.59 and a 1-year high of $95.30. The firm has a market cap of $62.13 billion, a price-to-earnings ratio of 11.62, a price-to-earnings-growth ratio of 0.39 and a beta of 1.69.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, January 31st. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.32 by $0.07. Celgene had a net margin of 26.48% and a return on equity of 114.66%. The firm had revenue of $4.04 billion for the quarter, compared to the consensus estimate of $3.98 billion. During the same quarter in the prior year, the company posted $2.00 earnings per share. On average, equities research analysts anticipate that Celgene Co. will post 10.01 earnings per share for the current year.

A number of research analysts recently issued reports on the stock. Cantor Fitzgerald reiterated a “buy” rating and set a $100.00 target price on shares of Celgene in a research report on Thursday, January 3rd. BidaskClub upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a research report on Wednesday, December 5th. Goldman Sachs Group upgraded shares of Celgene from a “sell” rating to a “neutral” rating and boosted their target price for the company from $71.00 to $88.00 in a research report on Thursday, January 3rd. Jefferies Financial Group downgraded shares of Celgene from a “buy” rating to a “hold” rating and set a $95.00 target price on the stock. in a research report on Friday, February 1st. Finally, reiterated a “buy” rating on shares of Celgene in a research report on Monday, December 3rd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $100.94.

ILLEGAL ACTIVITY NOTICE: “Celgene Co. (CELG) Stake Lifted by Mackay Shields LLC” was originally posted by PressOracle and is the property of of PressOracle. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://pressoracle.com/news/2019/03/17/celgene-co-celg-stake-lifted-by-mackay-shields-llc.html.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Further Reading: What causes a recession?

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.